Mobocertinib
Mobocertinib was the first oral drug for EGFR exon 20 insertion lung cancer, approved in 2021 and withdrawn in 2023-24 after its confirmatory trial failed.
Accelerated approval 2021 (28% response after platinum). EXCLAIM-2 (2023) failed to beat chemotherapy first line; Takeda withdrew it globally (US withdrawal completed 2024). Amivantamab and sunvozertinib now cover the indication.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2021 | EGFR exon 20 insertion NSCLC after platinum — Withdrawn 2023-24 |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Mobocertinib" OR ABSTRACT:"Mobocertinib" OR TITLE:"Exkivity" OR ABSTRACT:"Exkivity") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Mobocertinib, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductSunvozertinib
Shares EGFR exon 20 insertion, EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductBrigatinib
Shares Takeda, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductDacomitinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductIxazomib
Shares Takeda, Small-molecule kinase inhibitors and the tag gap-fill.
- ProductEnsartinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductAfatinib
Shares EGFR, Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductCeritinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.
- ProductTaletrectinib
Shares Small-molecule kinase inhibitors, Non-small-cell lung cancer and the tag gap-fill.